Result of AGM

RNS Number : 9918F
Oxford Biomedica PLC
23 May 2017
 

 

 

 

 

 

 

Oxford BioMedica Annual General Meeting

 

London, UK - 23 May 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

 

·      Resolution 7: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;

·      Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and

·      Resolution 9: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.

 

Certified copies of the document setting out the above resolutions passed at the 2017 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.

 

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (19 May 2017) there were 3,088,326,065 1p ordinary shares in issue, each carrying one vote per share.

 

 

 

Resolution

 

Votes

For

Votes at

Chairman's

Discretion

Votes at

other proxy

Discretion

 

Votes

Against

 

Votes

Withheld

 

Total

votes cast

Result









Ordinary resolutions














1

1,888,465,188

802,799

6,958,793

604,970

398,641

1,897,230,391

Passed









2

1,601,919,465

928,694

6,958,793

4,701,911

282,721,528

1,897,230,391

Passed









3

1,880,264,095

868,254

6,958,793

1,126,450

8,012,799

1,897,230,391

Passed

4

 

1,880,712,558

 

872,425

 

6,958,793

 

664,300

 

8,022,315

 

1,897,230,391

 

Passed









5

1,813,674,842

880,635

6,958,793

75,322,036

394,085

1,897,230,391

Passed









6

1,887,924,882

925,661

6,958,793

857,070

563,985

1,897,230,391

Passed

Special resolutions

 

 







7

1,774,042,262

1,002,090

6,958,793

1,619,809

113,607,437

1,897,230,391

Passed









8

1,887,104,129

1,002,090

6,958,793

1,557,942

607,437

1,897,230,391

Passed

























9

1,879,803,796

1,001,125

6,958,793

9,042,530

424,147

1,897,230,391

Passed

















 

 

 

 

- Ends -

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 

 

 

Tel: +44 (0)20 3709 5700

Notes for editors

 

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSEFFDDFWSESI
UK 100